{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:05:34Z","timestamp":1789247134704,"version":"build-2803163510"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004386","name":"University of Malaya","doi-asserted-by":"publisher","award":["BKP042-2025-ECRG"],"award-info":[{"award-number":["BKP042-2025-ECRG"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116803","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:12:43Z","timestamp":1778875963000},"page":"116803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Navigating the future: An updated review and prospects for breast cancer vaccines"],"prefix":"10.1016","volume":"182","author":[{"given":"Alia Syazana Mohd","family":"Roslei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasniza Zaman","family":"Huri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisalina Ahmad","family":"Fisol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyah Ayu Oktavianie A.","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif Mohamed","family":"Sofian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fauzi Abd","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Hassan","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didi Erwandi Mohamad","family":"Haron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdin Shakirin Mohamad","family":"Norpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Khusairi","family":"Azemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Luqman","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116803_bb0005","author":"WHO"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12032-022-01804-x","article-title":"Risk factors for breast cancer in women: An update review","volume":"39","author":"Fakhri","year":"2022","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002024","article-title":"BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history","volume":"3","author":"Toh","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116803_bib1231","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jama.2019.11885","article-title":"Medicationuse to reduce risk of breast cancer: US Preventive Services Task ForceRecommendation Statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2026.116803_bb0020","article-title":"Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/life14030402","article-title":"Breast cancer exposomics","volume":"14","author":"Neagu","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.intimp.2026.116803_bb0035","series-title":"Breast Cancer Surgery","author":"Czajka","year":"2023"},{"key":"10.1016\/j.intimp.2026.116803_bb0040","series-title":"JAMA Oncology","first-page":"785","article-title":"Chemotherapy near the end of life first-and third and fourth (line)-do no harm","volume":"vol. 1, Number 6","author":"Blanke","year":"2015"},{"key":"10.1016\/j.intimp.2026.116803_bb0045","first-page":"721","article-title":"Breast cancer: An overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer: Targets Therapy"},{"key":"10.1016\/j.intimp.2026.116803_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2021.102793","article-title":"Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?","volume":"70","author":"Prihantono","year":"2021","journal-title":"Ann. Med. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2026.116803_bb0070","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.meddos.2016.06.005","article-title":"Radiation therapy for breast cancer: literature review","volume":"41","author":"Balaji","year":"2016","journal-title":"Med. Dosim."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116803_bb0090","article-title":"Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment","volume":"2022","author":"Yang","year":"2022","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0095","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116803_bb0100","article-title":"Gold-promoting-satellite to boost photothermal conversion efficiency of cu2-se for triple-negative breast cancer targeting therapy","volume":"18","author":"Bao","year":"2022","journal-title":"Mater. Today Nano"},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bmc.2016.01.044","article-title":"Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein","volume":"24","author":"Cai","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"25","key":"10.1016\/j.intimp.2026.116803_bb0110","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1021\/ja4046857","article-title":"\u2018Multicopy multivalent\u2019 glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines","volume":"135","author":"Parry","year":"2013","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0115","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1021\/acs.nanolett.0c01140","article-title":"Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Nano Lett."},{"issue":"23","key":"10.1016\/j.intimp.2026.116803_bb0120","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1021\/acs.nanolett.1c03243","article-title":"Engineered nanovaccine targeting clec9a + dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist","volume":"21","author":"Gou","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.intimp.2026.116803_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120218","article-title":"Chitosan\/\u03b3-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer","volume":"257","author":"Castro","year":"2020","journal-title":"Biomaterials"},{"issue":"31","key":"10.1016\/j.intimp.2026.116803_bb0130","doi-asserted-by":"crossref","first-page":"17535","DOI":"10.1021\/acsami.5b05497","article-title":"Lipopeptide-coated iron oxide nanoparticles as potential glycoconjugate-based synthetic anticancer vaccines","volume":"7","author":"Sungsuwan","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2026.116803_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120897","article-title":"Combining anti-PD-1 antibodies with mn2+-drug coordinated multifunctional nanoparticles for enhanced cancer therapy","volume":"275","author":"Geng","year":"2021","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb0140","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acsomega.0c05924","article-title":"Liposomal dendritic cell vaccine in breast cancer immunotherapy","volume":"6","author":"Pan","year":"2021","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0145","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.biomaterials.2012.10.018","article-title":"A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth","volume":"34","author":"Wang","year":"2013","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.intimp.2026.116803_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185099","article-title":"Conjugated nanoliposome with the HER2\/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model","volume":"12","author":"Razazan","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/21691401.2019.1576702","article-title":"P435 HER2\/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer","volume":"47","author":"Farzad","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116803_bb0160","series-title":"Biologics: Targets and Therapy","first-page":"27","article-title":"Therapeutic Vaccines and cancer: Focus on DPX-0907","author":"Karkada","year":"2014"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-10-28","article-title":"Phase i clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion","volume":"10","author":"Hamilton","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116803_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00227","article-title":"Tumor heterogeneity in breast cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2026.116803_bb0175","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin. Med. Insights: Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/medicina60010168","article-title":"Exploring biomarkers in breast cancer: hallmarks of diagnosis, treatment, and follow-up in clinical practice","volume":"60","author":"Lopez-Gonzalez","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.intimp.2026.116803_bb0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amsu.2019.11.021","article-title":"Molecular classification of breast cancer: A retrospective cohort study","volume":"49","author":"Al-thoubaity","year":"2020","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.intimp.2026.116803_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1321654","article-title":"Editorial: heterogeneity in breast cancer: clinical and therapeutic implications","volume":"14","author":"Carlino","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/diagnostics11091555","article-title":"Breast Cancer Heterogeneity","volume":"11","author":"Fumagalli","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.intimp.2026.116803_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117009","article-title":"Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations","volume":"239","author":"Janu\u0161kevi\u010dien\u0117","year":"2019","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0205","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/cancers12061660","article-title":"Uncovering the tumor antigen landscape: what to know about the discovery process","volume":"12","author":"Feola","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116803_bb0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2019.12.002","article-title":"Expression of tumor-associated antigens in breast cancer subtypes","volume":"49","author":"Curigliano","year":"2020","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"Npj Breast Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0220","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000342164","article-title":"Tumor-associated antigens in breast cancer","volume":"7","author":"Criscitiello","year":"2012","journal-title":"Breast Care (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2026.116803_bb0225","article-title":"Neoantigen: A new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0230","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.37349\/emed.2023.00197","article-title":"The differential effect of the immune system in breast cancer","author":"Bondhopadhyay","year":"2023","journal-title":"Explor. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jncc.2024.01.004","article-title":"The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy","volume":"4","author":"Nicolini","year":"2024","journal-title":"J. Natl. Cancer Center"},{"key":"10.1016\/j.intimp.2026.116803_bb0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies","volume":"52","author":"Hammerl","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2026.116803_bb0245","series-title":"Current Biology","first-page":"R921","article-title":"The tumor microenvironment","author":"Anderson","year":"2020"},{"issue":"681","key":"10.1016\/j.intimp.2026.116803_bib1232","article-title":"Cell membrane vaccine delivery system: A review of the recent advances against breast cancer","volume":"20","author":"Hilles","year":"2025","journal-title":"Int J Pharm."},{"issue":"13","key":"10.1016\/j.intimp.2026.116803_bb0250","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.3390\/ijms25137346","article-title":"Complex role of regulatory t cells (tregs) in the tumor microenvironment: their molecular mechanisms and bidirectional effects on cancer progression","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0255","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory t cells (tregs) and their therapeutic potential against autoimmune disorders \u2013 advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb0260","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory t cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2026.116803_bb0265","article-title":"Myeloid derived suppressor cells in tumor microenvironment: interaction with innate lymphoid cells","volume":"61\u201364","author":"Tumino","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJN.S441135","article-title":"TME-related biomimetic strategies against cancer","volume":"19","author":"Peng","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"S2","key":"10.1016\/j.intimp.2026.116803_bb0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy, Asthma Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0280","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2019.98","article-title":"Cell-mediated immune resistance in cancer","author":"Wang","year":"2019","journal-title":"Cancer Drug Resistance."},{"key":"10.1016\/j.intimp.2026.116803_bb0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clim.2015.10.001","article-title":"Bench to bedside: NK cells and control of metastasis","volume":"177","author":"Krasnova","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0290","article-title":"New insights into the role of macrophages in cancer immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0b013e3182518e83","article-title":"Cancer and innate immune system interactions","volume":"35","author":"Liu","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.116803_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110952","article-title":"Immunogenicity of cancer cells: An overview","volume":"113","author":"Singh","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116803_bb0305","doi-asserted-by":"crossref","unstructured":"Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., Mizan, M. F. R., & Emran, T. Bin (2023). Role of t cells in cancer immunotherapy: opportunities and challenges. In Cancer pathogenesis and therapy (vol. 1, number 2, pp. 116\u2013126). Chinese Medical Association. Doi: https:\/\/doi.org\/10.1016\/j.cpt.2022.12.002.","DOI":"10.1016\/j.cpt.2022.12.002"},{"key":"10.1016\/j.intimp.2026.116803_bb0310","series-title":"Cancer Research","first-page":"5591","article-title":"The emerging role of b cells in tumor immunity","volume":"vol. 76","author":"Tsou","year":"2016"},{"key":"10.1016\/j.intimp.2026.116803_bb0315","series-title":"Trends in Cancer","first-page":"747","article-title":"B Lymphocytes and Cancer: A Love\u2013Hate Relationship","volume":"vol. 2","author":"Yuen","year":"2016"},{"key":"10.1016\/j.intimp.2026.116803_bb0320","series-title":"Review Series THERAPEUTIC ANTIBODIES CTLA-4: a moving target in immunotherapy","volume":"vol. 131, Number 1","author":"Rowshanravan","year":"2018"},{"key":"10.1016\/j.intimp.2026.116803_bb0325","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021). CTLA-4 in regulatory t cells for cancer immunotherapy. In Cancers (vol. 13, pp. 1\u201318). MDPI AG. Number 6 Doi: https:\/\/doi.org\/10.3390\/cancers13061440.","DOI":"10.3390\/cancers13061440"},{"key":"10.1016\/j.intimp.2026.116803_bb0330","series-title":"International Immunopharmacology","article-title":"Mechanisms of immune escape in the cancer immune cycle","volume":"vol. 86","author":"Tang","year":"2020"},{"key":"10.1016\/j.intimp.2026.116803_bb1220","author":"National Cancer Institute, N"},{"key":"10.1016\/j.intimp.2026.116803_bb0335","unstructured":"Han, Y., Liu, D., & Li, L. (2020). PD-1\/PD-L1 pathway: current researches in cancer. In Am j cancer res (vol. 10, number 3). www.ajcr.us\/."},{"key":"10.1016\/j.intimp.2026.116803_bb0340","series-title":"Frontiers in Pharmacology","article-title":"The evasion mechanisms of Cancer immunity and drug intervention in the tumor microenvironment","volume":"vol. 13","author":"Kim","year":"2022"},{"key":"10.1016\/j.intimp.2026.116803_bb0345","series-title":"Seminars in Cancer Biology","first-page":"S185","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"vol. 35","author":"Vinay","year":"2015"},{"key":"10.1016\/j.intimp.2026.116803_bb1225","author":"National Cancer Institute, N"},{"key":"10.1016\/j.intimp.2026.116803_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2025.100210","article-title":"Understanding drug resistance in breast cancer: mechanisms and emerging therapeutic strategies","volume":"26","author":"Gautam","year":"2025","journal-title":"Med. Drug Discov."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0355","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/ph18060895","article-title":"Multidrug resistance: are we still afraid of the big bad wolf","volume":"18","author":"Alhazza","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2026.116803_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117486","article-title":"The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents","volume":"95","author":"Yu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0365","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0370","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/cpt.2207","article-title":"Vaccines: underlying principles of design and testing","volume":"109","author":"Kallon","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116803_bb0375","doi-asserted-by":"crossref","unstructured":"Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. In Nature reviews immunology (vol. 21, pp. 83\u2013100). Nature Research. Number 2 Doi: https:\/\/doi.org\/10.1038\/s41577-020-00479-7.","DOI":"10.1038\/s41577-020-00479-7"},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0380","first-page":"260","article-title":"Current perspectives and future prospects of mRNA vaccines against viral diseases: A brief review","volume":"11","author":"Koppu","year":"2022","journal-title":"Int. J. Mol. Cell. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/pharmaceutics13020140","article-title":"Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants","volume":"13","author":"Bouazzaoui","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0390","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s43556-024-00222-x","article-title":"Prophylactic and therapeutic vaccine development: advancements and challenges","volume":"5","author":"Weerarathna","year":"2024","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0395","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2457187","article-title":"Mini-review on the therapeutic vaccines targeting chronic infectious diseases: evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers","volume":"21","author":"Woo","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb0400","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.4161\/21645515.2014.980707","article-title":"Vaccines versus immunotherapy: overview of approaches in deciding between options","volume":"10","author":"Dalgleish","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116803_bb0405","series-title":"Drug Discovery Today","first-page":"1347","article-title":"Cancer vaccines: An unkept promise?","author":"Kamath","year":"2021"},{"key":"10.1016\/j.intimp.2026.116803_bb0410","doi-asserted-by":"crossref","unstructured":"Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2022). Therapeutic vaccines for breast cancer: has the time finally come? In European journal of cancer (vol. 160, pp. 150\u2013174). Elsevier ltd. Doi: https:\/\/doi.org\/10.1016\/j.ejca.2021.10.027.","DOI":"10.1016\/j.ejca.2021.10.027"},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0415","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","article-title":"Cancer vaccines: steering t cells down the right path to eradicate tumors","volume":"9","author":"Ott","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0425","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of t cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116803_bb0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","article-title":"Therapeutic cancer vaccines: from initial findings to prospects","volume":"196","author":"Song","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2026.116803_bb0435","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2019.02.002","article-title":"Studying interactions between dendritic cells and t cells in vivo","volume":"58","author":"Chudnovskiy","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105068","article-title":"The role of therapeutic cancer vaccines in the modern immunotherapy era: state of the art with recent progress and future challenges","volume":"217","author":"Rota","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2026.116803_bb0445","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ t cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0450","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0455","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating b cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0460","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543019","article-title":"Tumor-infiltrating b cells produce tumor-specific antibodies and may contribute to suppressing tumor in head and neck squamous cell carcinoma","volume":"14","author":"Sameshima","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2026.116803_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.135541","article-title":"Old concepts, new tricks: how peptide vaccines are reshaping cancer immunotherapy?","volume":"279","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2026.116803_bb0470","doi-asserted-by":"crossref","unstructured":"Solinas, C., Aiello, M., Migliori, E., Willard-Gallo, K., & Emens, L. A. (2020). Breast cancer vaccines: heeding the lessons of the past to guide a path forward. In Cancer treatment reviews (vol. 84). W.B. Saunders Ltd. Doi: https:\/\/doi.org\/10.1016\/j.ctrv.2019.101947.","DOI":"10.1016\/j.ctrv.2019.101947"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0475","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/vaccines11121783","article-title":"Cancer vaccines in the immunotherapy era: promise and potential","volume":"11","author":"Verma","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2026.116803_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.626463","article-title":"Prophylactic cancer vaccines engineered to elicit specific adaptive immune response","volume":"11","author":"Crews","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0490","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri.2017.140","article-title":"The dawn of vaccines for cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0500","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/cancers8060056","article-title":"Targeted vaccination against human \u03b1-Lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer","volume":"8","author":"Tuohy","year":"2016","journal-title":"Cancers"},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.116803_bb0505","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1125","article-title":"Phase i trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC)","volume":"40","author":"Budd","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0510","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nm.2161","article-title":"An autoimmune-mediated strategy for prophylactic breast cancer vaccination","volume":"16","author":"Jaini","year":"2010","journal-title":"Nat. Med."},{"issue":"33","key":"10.1016\/j.intimp.2026.116803_bb0515","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1016\/j.vaccine.2022.06.062","article-title":"Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer","volume":"40","author":"Odales","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0520","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1471-2407-8-297","article-title":"Amplification of HER2 is a marker for global genomic instability","volume":"8","author":"Ellsworth","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.116803_bb0525","series-title":"HER2 and epigenetic modifications in tumorigenesis: mechanisms and therapeutic implications","author":"Ye","year":"2025"},{"issue":"24","key":"10.1016\/j.intimp.2026.116803_bb0530","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2026.116803_bb0535","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0540","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12935-022-02678-9","article-title":"Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer","volume":"22","author":"Taheri","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0545","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2015.11.001","article-title":"Immunologic approaches to cancer prevention\u2014current status, challenges, and future perspectives","volume":"43","author":"Wojtowicz","year":"2016","journal-title":"Semin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0550","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.intimp.2026.116803_bb0555","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.3390\/cancers13153875","article-title":"Cancer-testis antigens in triple-negative breast cancer: role and potential utility in clinical practice","volume":"13","author":"Lam","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116803_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2021.100402","article-title":"The utility of serum tumor markers CEA and CA 15\u20133 for breast cancer prognosis and their association with clinicopathological parameters","volume":"28","author":"Uygur","year":"2021","journal-title":"Cancer Treatment Res. Commun."},{"key":"10.1016\/j.intimp.2026.116803_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114685","article-title":"Dendritic cell vaccines in breast cancer: immune modulation and immunotherapy","volume":"162","author":"Qian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116803_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106422","article-title":"Recent advancements in the cancer vaccines: A review. In","volume":"102","author":"Kawish","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.intimp.2026.116803_bb0575","series-title":"Molecular Aspects of Medicine","article-title":"Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development","volume":"vol. 95","author":"Gautam","year":"2024"},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0580","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic Cell\u2013Based Cancer Vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0585","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2326-6066.CIR-21-0454","article-title":"Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ th1 responses and potential use as a cancer vaccine","volume":"10","author":"Basu","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116803_bb0590","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omto.2021.05.006","article-title":"CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper t cell responses against breast cancer stem cells","volume":"22","author":"Tay","year":"2021","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.intimp.2026.116803_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789078","article-title":"Phase i clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy","volume":"11","author":"Maeng","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-025-00742-x","article-title":"A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer","volume":"11","author":"Soliman","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2026.116803_bb0605","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb0610","series-title":"Journal of Oncology","article-title":"Development of Peptide-Based Vaccines for Cancer","volume":"vol. 2022","author":"Abd-Aziz","year":"2022"},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bib1233","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/ph16070923","article-title":"Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects","volume":"16","author":"Nordin","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0615","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb0650","first-page":"3407","article-title":"Toxicity, immunogenicity, and induction of e75-specific tumor-lytic CTLs by HER-2 peptide e75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer","volume":"8","author":"Murray","year":"2002","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2026.116803_bb0655","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: A randomized, multicenter, phase III clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0620","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/vaccines8040706","article-title":"DC-Based Vaccines for Cancer Immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2026.116803_bb0625","doi-asserted-by":"crossref","unstructured":"Najafi, S., & Mortezaee, K. (2023). Advances in dendritic cell vaccination therapy of cancer. In Biomedicine and pharmacotherapy (vol. 164). Elsevier Masson s.r.l. Doi: https:\/\/doi.org\/10.1016\/j.biopha.2023.114954.","DOI":"10.1016\/j.biopha.2023.114954"},{"key":"10.1016\/j.intimp.2026.116803_bb0630","doi-asserted-by":"crossref","unstructured":"Kozak, M., & Hu, J. (2024). DNA vaccines: their formulations, engineering and delivery. In Vaccines (vol. 12, number 1). Multidisciplinary Digital Publishing Institute (MDPI). Doi: https:\/\/doi.org\/10.3390\/vaccines12010071.","DOI":"10.3390\/vaccines12010071"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0635","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/genes13122287","article-title":"Third-generation vaccines: features of nucleic acid vaccines and strategies to improve their efficiency","volume":"13","author":"Melo","year":"2022","journal-title":"Genes"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0640","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/gels10120838","article-title":"Whole-cell vaccine preparation through prussian blue nanoparticles-elicited immunogenic cell death and loading in gel microneedles patches","volume":"10","author":"Fu","year":"2024","journal-title":"Gels"},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0645","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: new prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116803_bb0660","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0665","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.4161\/hv.26088","article-title":"Advances in the study of HLA-restricted epitope vaccines","volume":"9","author":"Zhao","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0670","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1940-6207.CAPR-22-0388","article-title":"Phase II trial of Nelipepimut-S peptide vaccine in women with ductal carcinoma in situ","volume":"16","author":"O\u2019Shea","year":"2023","journal-title":"Cancer Prev. Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116803_bb0675","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/vaccines12080950","article-title":"Advancements and challenges in peptide-based cancer vaccination: A multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0680","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.intimp.2026.116803_bb0685","article-title":"In silico design and in vitro validation of a multi-epitope peptide vaccine targeting triple-negative breast cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.116803_bb0690","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS610","volume":"40","author":"Chumsri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb0695","series-title":"Cancer Vaccines as Immunotherapy of Cancer","first-page":"227","article-title":"Nucleic acid-based vaccines","author":"Conforti","year":"2022"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0705","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12032-023-02060-3","article-title":"The future of cancer immunotherapy: DNA vaccines leading the way","volume":"40","author":"Pandya","year":"2023","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116803_bb0710","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29040","article-title":"Co-delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced th1-dominant humoral and cellular immunity against SARS-CoV-2","volume":"95","author":"Liao","year":"2023","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0715","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/sji.12633","article-title":"MUC1- and survivin-based DNA vaccine combining immunoadjuvants CpG and interleukin-2 in a bicistronic expression plasmid generates specific immune responses and antitumour effects in a murine colorectal carcinoma model","volume":"87","author":"Liu","year":"2018","journal-title":"Scand. J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0720","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-induced memory CD8+ t cells provide clinical benefit in HER2 expressing breast cancer: A mouse to human translational study","volume":"25","author":"Crosby","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2026.116803_bb0725","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/jco.2015.33.15_suppl.3081","article-title":"Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal t cell and antibody responses against HER2","volume":"33","author":"Gwin","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116803_bb0730","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103458","article-title":"Current state of, prospects for, and obstacles to mRNA vaccine development","volume":"28","author":"Aljabali","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0740","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/mr.59.3.423-450.1995","article-title":"MRNA stability in mammalian cells","volume":"59","author":"Ross","year":"1995","journal-title":"Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0745","article-title":"Prospects and challenges in developing mRNA vaccines for infectious diseases and oncogenic viruses","volume":"12","author":"Kutikuppala","year":"2024","journal-title":"Med. Sci. (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2026.116803_bb0750","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.annonc.2020.08.209","article-title":"88MO t-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer","volume":"31","author":"Schmidt","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0755","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current developments and challenges of mRNA vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.116803_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol. Asp. Med."},{"issue":"17","key":"10.1016\/j.intimp.2026.116803_bb0765","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014A literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0770","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13046-023-02744-8","article-title":"RWTC-MBTA: Autologous vaccine prevents metastases via antitumor immune responses","volume":"42","author":"Ye","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0775","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/vaccines11071254","article-title":"Introduction of an ultraviolet c-irradiated 4T1 murine breast cancer whole-cell vaccine model","volume":"11","author":"Szebeni","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0780","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-021-00872-4","article-title":"Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation","volume":"13","author":"Li","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2026.116803_bb0785","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molimm.2025.06.003","article-title":"DNA vaccination combined with immune checkpoint inhibition eradicates tumors, inducing life-long immunity against breast cancer in mice","volume":"184","author":"Dom\u00ednguez-Romero","year":"2025","journal-title":"Mol. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116803_bb0790","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.3390\/cancers13194958","article-title":"HER2\/neu-based peptide vaccination-pulsed with b-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model","volume":"13","author":"Nordin","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004702","article-title":"Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model","volume":"10","author":"Kang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"23","key":"10.1016\/j.intimp.2026.116803_bb0800","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.3390\/ijms232315130","article-title":"Breast cancer vaccine containing a novel toll-like receptor 7 agonist and an aluminum adjuvant exerts antitumor effects","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb0805","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/vaccines11030644","article-title":"Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: A potential neoadjuvant t cell immunotherapy for triple negative breast cancer: A preliminary study","volume":"11","author":"Burkholz","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0810","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41698-023-00461-1","article-title":"Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention","volume":"7","author":"Lee","year":"2023","journal-title":"Npj Precision Oncol."},{"issue":"34","key":"10.1016\/j.intimp.2026.116803_bb0815","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116803_bb0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer vaccines, adjuvants, and delivery systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2022.100667","article-title":"A comparison of cancer vaccine adjuvants in clinical trials","volume":"34","author":"Marriott","year":"2023","journal-title":"Cancer Treatment Res. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb0830","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0835","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2026.116803_bb0840","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.3390\/cancers17213582","article-title":"Enhancing cancer therapy with TLR7\/8 agonists: applications in vaccines and combination treatments","volume":"17","author":"Mondal","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0845","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40425-017-0295-5","article-title":"A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer","volume":"5","author":"Dillon","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb0850","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/imm.13643","article-title":"Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8 + t cells and enhancing their function","volume":"169","author":"Shi","year":"2023","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102530","article-title":"Conjugated STING agonists","volume":"36","author":"Qu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7370","key":"10.1016\/j.intimp.2026.116803_bb0860","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature10429","article-title":"STING is a direct innate immune sensor of cyclic di-GMP","volume":"478","author":"Burdette","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0865","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.7150\/thno.107200","article-title":"PH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116803_bb0870","series-title":"Advances in therapeutic cancer vaccines","first-page":"191","author":"Wong","year":"2016"},{"key":"10.1016\/j.intimp.2026.116803_bb0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1459394","article-title":"Adjuvants: Classification, Modus Operandi, and Licensing","volume":"2016","author":"Apost\u00f3lico","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb0880","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence","volume":"27","author":"Mittendorf","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb0885","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the e75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb0890","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","author":"Brown","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2026.116803_bb0895","series-title":"Advances in Cancer Research","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/B978-0-12-800249-0.00002-0","article-title":"Therapeutic cancer vaccines","volume":"vol. 121","author":"Schlom","year":"2014"},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb0900","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.urology.2014.12.029","article-title":"Current and emerging immunotherapies for castration-resistant prostate cancer","volume":"85","author":"Saad","year":"2015","journal-title":"Urology"},{"issue":"29","key":"10.1016\/j.intimp.2026.116803_bb0905","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2011.11.058","article-title":"Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer","volume":"30","author":"Sims","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb0910","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb0915","doi-asserted-by":"crossref","first-page":"10110","DOI":"10.18632\/oncotarget.24118","article-title":"A phase-1\/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer","volume":"9","author":"Soliman","year":"2018","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.intimp.2026.116803_bb0920","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2016.34.15_suppl.1086","article-title":"Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts)","volume":"34","author":"O\u2019Shaughnessy","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4_Supplement","key":"10.1016\/j.intimp.2026.116803_bb0925","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-P3-05-01","article-title":"Abstract p3-05-01: immune and transcriptional signatures of dendritic dell (DC) vaccination combined with chemotherapy in locally advanced, triple-negative breast cancer (TNBC) patients","volume":"78","author":"Palucka","year":"2018","journal-title":"Cancer Res."},{"issue":"5_Supplement","key":"10.1016\/j.intimp.2026.116803_bb0930","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P2-02-02","article-title":"Abstract p2-02-02: phase i trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer","volume":"83","author":"Stanton","year":"2023","journal-title":"Cancer Res."},{"issue":"58","key":"10.1016\/j.intimp.2026.116803_bb0935","doi-asserted-by":"crossref","first-page":"99161","DOI":"10.18632\/oncotarget.21959","article-title":"Targeting tumor-associated carbohydrate antigens: A phase i study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects","volume":"8","author":"Hutchins","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.intimp.2026.116803_bb0940","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.18632\/oncotarget.28083","article-title":"P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses","volume":"12","author":"Makhoul","year":"2021","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.intimp.2026.116803_bb0945","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/jco.2013.31.15_suppl.3005","article-title":"Randomized phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: A planned interim analysis","volume":"31","author":"Trappey","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb0950","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/imt.14.22","article-title":"The HER2 peptide Nelipepimut-S (e75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response","volume":"6","author":"Schneble","year":"2014","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0955","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00262-011-1141-0","article-title":"Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines","volume":"61","author":"Bilusic","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116803_bb0960","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1090533","article-title":"Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials","volume":"14","author":"McCarthy","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0965","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf016","article-title":"Cancer vaccine trial evaluations: Immunobridging and potential immunological endpoints","volume":"5","author":"Hussain","year":"2024","journal-title":"Immunotherapy Adv."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb0970","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/onco5010011","article-title":"The role of therapeutic vaccines in cancer immunotherapy","volume":"5","author":"Baxevanis","year":"2025","journal-title":"Onco"},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb0975","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.4161\/hv.27586","article-title":"Cancer vaccines: what do we need to measure in clinical trials?","volume":"10","author":"Kudrin","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116803_bb0980","author":"Sahin"},{"key":"10.1016\/j.intimp.2026.116803_bb0985","author":"Bender"},{"key":"10.1016\/j.intimp.2026.116803_bb0990","author":"Ashburn"},{"key":"10.1016\/j.intimp.2026.116803_bb0995","author":"Ciaramella"},{"key":"10.1016\/j.intimp.2026.116803_bb1000","author":"Briones"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41698-021-00165-4","article-title":"Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics","volume":"5","author":"Li","year":"2021","journal-title":"Npj Precision Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb1010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1399754","article-title":"Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches","volume":"15","author":"Naji","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.54254\/2753-8818\/3\/20220264","article-title":"Challenge and solution for cancer vaccine therapy for breast cancer","volume":"3","author":"Tao","year":"2023","journal-title":"Theor. Nat. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb1025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200646","article-title":"Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy","volume":"13","author":"Czajka-Francuz","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb1030","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/app14051809","article-title":"Exploring the potential of nanoparticles in the treatment of breast cancer: current applications and future directions","volume":"14","author":"Patel","year":"2024","journal-title":"Appl. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb1035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(25)00096-8","article-title":"Personalised cancer vaccines and new regulatory struggles","volume":"26","author":"The Lancet Oncology","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116803_bb1040","article-title":"Realizing the promise of breast cancer vaccines","volume":"35","author":"Soliman","year":"2012","journal-title":"Vaccine: Develop. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2026.116803_bb1045","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/vaccines10122011","article-title":"Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects","volume":"10","author":"Gupta","year":"2022","journal-title":"Vaccines"},{"issue":"17","key":"10.1016\/j.intimp.2026.116803_bb1050","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1021\/acsnano.4c15765","article-title":"Cancer nanovaccines: mechanisms, design principles, and clinical translation","volume":"19","author":"Zaccariotto","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.116803_bb1055","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","volume":"19","author":"Singh","year":"2025","journal-title":"Oncol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s44272-025-00039-x","article-title":"Therapeutic vaccine strategies in cancer: advances, challenges, and future directions","volume":"4","author":"Wang","year":"2025","journal-title":"Clin. Cancer Bull."},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb1065","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/JLB.5BT0420-585RR","article-title":"Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside","volume":"108","author":"Roy","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116803_bb1070","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"MRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2026.116803_bb1075","doi-asserted-by":"crossref","unstructured":"Hsu, C. Y., Rheima, A. M., Kadhim, M. M., Ahmed, N. N., Mohammed, S. H., Abbas, F. H., Abed, Z. T., Mahdi, Z. M., Abbas, Z. S., Hachim, S. K., Ali, F. K., Mahmoud, Z. H., & Kianfar, E. (2023). An overview of nanoparticles in drug delivery: properties and applications. In South African journal of chemical engineering (vol. 46, pp. 233\u2013270). Elsevier B.V. Doi: https:\/\/doi.org\/10.1016\/j.sajce.2023.08.009.","DOI":"10.1016\/j.sajce.2023.08.009"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12951-024-02311-z","article-title":"The quest for nanoparticle-powered vaccines in cancer immunotherapy","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116803_bb1085","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1039\/C9NR08958F","article-title":"Nanoparticle formulated vaccines: opportunities and challenges","volume":"12","author":"Lung","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.intimp.2026.116803_bb1090","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2025.1564267","article-title":"Smart nanoparticle delivery of cancer vaccines enhances tumor immune responses: A review","volume":"7","author":"Qiu","year":"2025","journal-title":"Front.Nanotechnol."},{"key":"10.1016\/j.intimp.2026.116803_bb1095","doi-asserted-by":"crossref","unstructured":"Elumalai, K., Srinivasan, S., & Shanmugam, A. (2024). Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. In Biomedical technology (vol. 5, pp. 109\u2013122). KeAi Communications Co. Doi: https:\/\/doi.org\/10.1016\/j.bmt.2023.09.001.","DOI":"10.1016\/j.bmt.2023.09.001"},{"key":"10.1016\/j.intimp.2026.116803_bb1230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.52711\/2321-5836.2024.00034","article-title":"Breast cancer: from etiology to therapeutic interventions","author":"Vardhan Singh","year":"2024","journal-title":"Res. J. Pharmacol. Pharmacodyn."},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb1100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2026.116803_bb1105","series-title":"Life Sciences","article-title":"Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy","volume":"vol. 291","author":"Behravan","year":"2022"},{"key":"10.1016\/j.intimp.2026.116803_bb1110","doi-asserted-by":"crossref","unstructured":"Wang, S., Zhu, Y., Du, S., & Zheng, Y. (2024b). Preclinical advances in LNP-CRISPR therapeutics for solid tumor treatment. In Cells (vol. 13, Number 7). Multidisciplinary Digital Publishing Institute (MDPI). Doi: https:\/\/doi.org\/10.3390\/cells13070568.","DOI":"10.3390\/cells13070568"},{"issue":"9","key":"10.1016\/j.intimp.2026.116803_bb1115","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10529-023-03383-x","article-title":"Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: A review","volume":"45","author":"Danaeifar","year":"2023","journal-title":"Biotechnol. Lett."},{"issue":"8","key":"10.1016\/j.intimp.2026.116803_bb1120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/1061186X.2018.1564923","article-title":"Chitosan-based nanotherapeutics for ovarian cancer treatment","volume":"27","author":"Alizadeh","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.intimp.2026.116803_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112824","article-title":"Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer","volume":"149","author":"Liu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116803_bb1130","article-title":"The application of and strategy for gold nanoparticles in cancer immunotherapy","volume":"12","author":"He","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116803_bb1135","doi-asserted-by":"crossref","DOI":"10.3389\/fmats.2022.857385","article-title":"Research advance in manganese nanoparticles in cancer diagnosis and therapy","volume":"9","author":"Nie","year":"2022","journal-title":"Front. Mater."},{"key":"10.1016\/j.intimp.2026.116803_bb1140","series-title":"E-Polymers","article-title":"Polymer-based nanocarriers for biomedical and environmental applications","volume":"vol. 23, Number 1","author":"Idris","year":"2023"},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb1145","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy: A review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb1150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.32628\/IJSRST24115112","article-title":"A review on \u2013 liposomes as a novel drug delivery system","volume":"11","author":"Jadhav","year":"2024","journal-title":"Int. J. Sci. Res. Sci. Technol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116803_bb1155","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.intimp.2026.116803_bb1160","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/17425247.2024.2400293","article-title":"Biodegradable nanoplatforms for antigen delivery: part i \u2013 state of the art review of polymeric nanoparticles for cancer immunotherapy","volume":"21","author":"Vega","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.intimp.2026.116803_bb1165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030775","article-title":"Smart polymeric nanoparticles in cancer immunotherapy","volume":"15","author":"Yu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.intimp.2026.116803_bb1170","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/pharmaceutics15051346","article-title":"Prospects for the use of metal-based nanoparticles as adjuvants for local cancer immunotherapy","volume":"15","author":"Naletova","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.intimp.2026.116803_bb1175","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/pharmaceutics14020435","article-title":"Recent developments in metallic nanomaterials for cancer therapy, diagnosing and imaging applications","volume":"14","author":"P\u0103duraru","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.intimp.2026.116803_bb1180","article-title":"Advanced nanomaterials for cancer therapy: gold, silver, and iron oxide nanoparticles in oncological applications","volume":"14","author":"Singh","year":"2025","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40820-024-01533-y","article-title":"Engineered cancer nanovaccines: A new frontier in cancer therapy","volume":"17","author":"Wang","year":"2025","journal-title":"Nano-Micro Lett."},{"issue":"7","key":"10.1016\/j.intimp.2026.116803_bb1190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220474","article-title":"Effective treatment of cancer metastasis using a dual-ligand nanoparticle","volume":"14","author":"Covarrubias","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2026.116803_bb1195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","article-title":"Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"509","key":"10.1016\/j.intimp.2026.116803_bb1200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116803_bb1205","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsnano.9b05679","article-title":"Overcoming the reticuloendothelial system barrier to drug delivery with a \u201cdon\u2019t-eat-us\u201d strategy","volume":"13","author":"Tang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.116803_bb1210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1357217","article-title":"Personalized cancer vaccine design using AI-powered technologies","volume":"15","author":"Kumar","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116803_bb1215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1394003","article-title":"Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy","volume":"15","author":"Bulashevska","year":"2024","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:07:22Z","timestamp":1789243642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":249,"alternative-id":["S1567576926006491"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116803","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the future: An updated review and prospects for breast cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116803"}}